Y Combinator AI portfolio in San Francisco

Invert is software that connects, structures, and activates your bioprocess data using AI to give development and manufacturing teams the clarity they need to move from experiment to milestone faster.

• Seed
• 40 employees
• Founded 2021

Abundant is an applied research lab building the simulation engine for superintelligence. We reconstruct real work as high-fidelity simulation, giving models an unbounded supply of worlds to practice, fail, and improve in.

• Pre-seed
• 34 employees
• Founded 2024

Verge Labs is a frontier AI lab building world models of human disease biology. Founded in 2015 and headquartered in San Francisco, Verge develops AI models trained on proprietary multimodal human tissue data to power target discovery, in-silico validation, patient stratification, indication prioritization, and biomarker prediction. Verge partners with pharmaceutical and biotech companies to accelerate the development of treatments for CNS diseases and other complex human conditions.Verge actively seeks a diverse applicant pool in order to build the strongest possible workforce. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.

• Series C
• 28 employees
• Founded 2015

Shasqi is a biotech company whose mission is to make cancer drugs more effective with click chemistry, a 2022 Nobel Prize-winning technology. Our unique CAPAC® platform uses click chemistry to activate cancer drugs directly at the tumor. This approach minimizes toxicity to healthy tissue, allowing us to push beyond the limits of traditional ADC and radiopharm approaches and deliver higher doses of cancer therapies to increase patient benefit. The first company to use click chemistry in humans, Shasqi is developing a pipeline of click-chemistry enabled assets. We are advancing our lead asset, a CEACAM5 binder with an MMAE protodrug, to the clinic in Spring 2027. Follow us here for ongoing updates. To learn more about Shasqi and CAPAC, visit us at www.shasqi.com.

• Grant
• 28 employees
• Founded 2015

Probably Genetic helps undiagnosed rare disease patients find answers to their symptoms in a matter of weeks. There are over 400 million people worldwide that have a rare disease — more than cancer and HIV patients combined. Half of those patients are currently undiagnosed and half of them are children, and it takes 5-7 years on average for these patients to get a diagnosis. With our system, patients can get answers in a matter of weeks. Our online Symptom Checker identifies rare disease patients using state-of-the-art machine learning models, gets them tested through our direct-to-consumer genetic testing service, and helps connect these patients to potentially life-saving treatments and advocacy communities. We partner with drug developers to offer sponsored testing programs that allow patients to access genetic testing for little to no cost.

• Series unknown
• 27 employees
• Founded 2018